Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Clinical trial NCT00304460 · COMPLETED
Trial details
- NCT number
- NCT00304460
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2006-03-13
- Primary completion
- 2014-02-27
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.